IN8bio Inc. (INAB)
NASDAQ: INAB
· Real-Time Price · USD
0.13
-0.02 (-11.38%)
At close: May 15, 2025, 3:59 PM
0.13
-0.38%
After-hours: May 15, 2025, 07:23 PM EDT
-11.38% (1D)
| Bid | 0.12 |
| Market Cap | 11.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.43M |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | -0.3 |
| Forward PE | -0.72 |
| Analyst | Buy |
| Ask | 0.13 |
| Volume | 17,778,698 |
| Avg. Volume (20D) | 1,235,840 |
| Open | 0.12 |
| Previous Close | 0.15 |
| Day's Range | 0.11 - 0.13 |
| 52-Week Range | 0.11 - 1.74 |
| Beta | 0.23 |
About INAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts19 hours ago
IN8bio shares are trading lower. The company annou...
Unlock content with
Pro Subscription
3 months ago
+13.59%
IN8bio shares are trading higher after the company announced new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100.
2 years ago · proactiveinvestors.com
IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatmentIN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan drug designation from the US Food and Drug Adminis...
